Roche moved to expand its trispecific T-cell engager pipeline by licensing Zymeworks’ ZW209, a DLL3-targeting construct designed to engage CD3 and CD28. The deal includes a $55 million upfront payment, with a further $40 million tied to initiating a Phase Ib program, plus up to $813 million in additional milestones. Zymeworks retains financial interest while Roche takes over worldwide development and commercialization under the agreement. The program is positioned against other DLL3-directed cell therapy efforts, including approaches in the competitive lung cancer immunotherapy landscape. The transaction underscores continued pharma appetite for early, differentiated multispecific platforms that can offer deeper or more durable responses if clinical activity holds up in later-stage trials.